The U.S. Food and Drug Administration announced on Friday that it has officially announced the end of national shortages Ozempic and Wegovydrugs for diabetes and weight loss.
The agency first announced a shortage of major ingredients for manufacturing Ozempic and Wegovy in 2022.
The FDA's announcement comes months after drugmaker Novo Nordisk told the agency that all doses of its Semaglutide products have been obtained nationwide. The company said in a statement that it confirmed the supply of prescription-only drugs, “now meeting or exceeding current and projected U.S. demand.”
“This update follows a conversation with the FDA, and Novo Nordisk's strength efforts to improve manufacturing capabilities, including a $6.5 billion investment in the U.S. this year,” the drugmaker said.
The FDA said compound pharmacies will now be allowed to continue making copies of semaglutides, usually only if they are inadequate.
The agency said that this leeway will last until April 22, for many pharmacies and outsourcing facilities on May 22, to outsource patients “to avoid unnecessary interference.”
This is similar to a copy of the FDA-granted compound pharmacy production Diabetes and weight loss pills from Eli LillyThe FDA's decision to declare a shortage of weight loss pills was filed in an ongoing lawsuit filed by outsourcing facilities.
Some sophisticated pharmacies and outsourcing facilities make millions of dollars manufacturing Copy of semaglutide and tirzepatide In recent years, amid their shortages as a range of companies deliver on drug demand.
The FDA is also facing calls for more damage Drug Forgeryincluding the attorney general from the state attorney general, urged the agency this week to stop illegal imports from overseas.
“Demand for medications for Mounjaro, Zepbough, Ozempic and Wegovy (GLP-1 drugs) surged, but shortages of supply and high costs jeopardize consumers for making money for wrongdoing people,” they wrote.
